Sensus Healthcare, Inc. (SRTS) - Q2 2024 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2024. Sensus Healthcare, Inc. is a manufacturer of radiation therapy devices sold globally, primarily in the U.S. dermatology market. In February 2024, the company formed a subsidiary, Sensus Healthcare Services, LLC, to provide operational healthcare services including leased equipment and physics oversight.
Key Financial Metrics
| Metric | Q2 2024 (3 Months) | Q2 2023 (3 Months) | YTD 2024 (6 Months) | YTD 2023 (6 Months) |
|---|---|---|---|---|
| Revenue | $9.24 million | $4.53 million | $19.90 million | $7.94 million |
| Gross Profit | $5.42 million | $2.62 million | $12.09 million | $4.24 million |
| Gross Margin | 58.7% | 57.9% | 60.7% | 53.4% |
| Net Income (Loss) | $1.61 million | ($0.38 million) | $3.89 million | ($2.27 million) |
| Diluted EPS | $0.10 | ($0.02) | $0.24 | ($0.14) |
| Cash and Equivalents | $18.97 million (as of June 30, 2024) | |||
| Debt | $0 outstanding (Available credit: $10 million) |
Material Changes vs. Prior Period
- Revenue Surge: Revenue increased 104.4% in Q2 and 151.9% YTD compared to the prior year. This growth was primarily driven by a higher volume of units sold to a single large U.S. customer.
- Profitability Turnaround: The company transitioned from a net loss in Q2 2023 to a net income of $1.61 million in Q2 2024. Operating income improved from a loss of $1.13 million to a profit of $1.98 million.
- Expense Management: Selling and marketing expenses decreased by 37.5% in Q2 due to reduced agency fees, lower headcount, and fewer trade show costs. General and administrative expenses increased 23.1% due to higher professional fees and compensation.
- Working Capital: Accounts receivable increased by $7.7 million to $18.3 million, largely due to sales concentration and extended payment terms with the primary customer. Inventory increased by $0.9 million in anticipation of future demand.
- Cash Flow: Net cash used in operating activities was $4.0 million for the six months ended June 30, 2024, an improvement from $5.3 million used in the prior year period, despite the increase in receivables.
Outlook, Risks, and Contingencies
- Customer Concentration Risk: One U.S. customer accounted for 83% of Q2 revenue and 92% of accounts receivable as of June 30, 2024. This creates significant dependency risk.
- Legal Proceedings: The company is under investigation by the Department of Justice regarding billing practices by a physician using its SRT-100 device. The company disputes any wrongdoing but cannot estimate potential costs.
- Internal Controls: Management identified a material weakness in internal controls over financial reporting related to IT general controls, specifically regarding access restrictions and segregation of duties. Remediation is in progress.
- Liquidity: The company maintains a $10 million revolving credit facility with Comerica Bank with no outstanding borrowings. It is compliant with financial covenants requiring $3.5 million in unencumbered liquid assets.
- Geopolitical Risks: While current global conflicts have not significantly impacted operations, the company monitors risks related to doing business in China and other foreign countries.
Investor Verification Checklist
- Customer Dependency: Verify the stability and payment reliability of the single customer representing 83% of Q2 revenue.
- Receivables Quality: Assess the collectability of the $18.3 million accounts receivable balance, given the concentration and extended payment terms.
- DOJ Investigation: Monitor updates regarding the Department of Justice investigation into billing practices.
- Internal Control Remediation: Track the progress of fixing the material weakness in IT general controls to ensure future financial reporting reliability.
- Inventory Levels: Confirm that the increased inventory levels align with actual demand to avoid potential write-downs.